Mercy BioAnalytics is dedicated to developing the means to detect cancer at an early stage. We are actively creating and validating the instrumentation necessary to detect multiple stage I solid tumors from a single blood draw with adequate sensitivity and ultra-high specificity (>99.9%). By helping patients find their cancer early, we hope to provide a better shot at a cure.
- Joseph Sedlak Scientific Founder
- Paul Blavin, MBA Co-Founder, Chairman of the Board
- Laura Bortolin, PhD Senior Research Scientist